Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEONASDAQ:MDNANASDAQ:SESNNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.68-1.2%$5.99$3.93▼$7.32$290.57M1.54686,476 shs949,561 shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsSESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shsSLGLSol-Gel Technologies$7.40+1.1%$7.35$3.34▼$16.50$20.62M1.132,957 shs1,146 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics0.00%-2.38%-6.35%+20.80%+35.61%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%SLGLSol-Gel Technologies0.00%-1.48%-0.27%+33.58%-17.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics4.0075 of 5 stars3.52.00.04.52.12.50.0MDNAMedicenna Therapeutics1.2772 of 5 stars3.50.00.00.00.01.70.0SESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies2.658 of 5 stars3.53.00.00.02.21.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 3.00Buy$19.25238.91% UpsideMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideSESNSesen Bio 0.00N/AN/AN/ASLGLSol-Gel Technologies 3.00Buy$40.00440.54% UpsideCurrent Analyst Ratings BreakdownLatest ABEO, MDNA, SESN, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025ABEOAbeona TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$19.005/16/2025ABEOAbeona TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$21.00 ➝ $20.005/15/2025ABEOAbeona TherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/30/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona TherapeuticsN/AN/AN/AN/A$1.01 per shareN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/ASESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00SLGLSol-Gel Technologies$12.10M1.70N/AN/A$10.36 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M-$1.27N/AN/AN/AN/A-118.82%-52.48%8/11/2025 (Estimated)MDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ASLGLSol-Gel Technologies-$10.58M-$4.70N/AN/AN/A-107.78%-43.98%-35.28%8/15/2025 (Estimated)Latest ABEO, MDNA, SESN, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million5/15/2025Q1 2025ABEOAbeona Therapeutics-$0.35-$0.24+$0.11-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.274.904.90MDNAMedicenna TherapeuticsN/A9.579.57SESNSesen BioN/A6.106.10SLGLSol-Gel TechnologiesN/A5.125.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%MDNAMedicenna Therapeutics12.38%SESNSesen Bio16.45%SLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics6.90%MDNAMedicenna Therapeutics33.10%SESNSesen Bio3.20%SLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A51.16 million48.40 millionOptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableSESNSesen Bio35203.49 million196.98 millionOptionableSLGLSol-Gel Technologies502.79 million933,000OptionableABEO, MDNA, SESN, and SLGL HeadlinesRecent News About These CompaniesSLGL Sol-Gel Technologies Ltd. - Seeking AlphaJune 26, 2025 | seekingalpha.comSol-Gel Technologies LtdJune 21, 2025 | morningstar.comMSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comQSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comSol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.April 17, 2025 | finanznachrichten.deSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.April 17, 2025 | globenewswire.comGlobal Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth AnalysisApril 7, 2025 | globenewswire.comSol-Gel Technologies Approves Reverse Share Split and Compensation Policy RenewalApril 1, 2025 | tipranks.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comBIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABEO, MDNA, SESN, and SLGL Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.68 -0.07 (-1.22%) As of 04:00 PM EasternAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Sesen Bio NASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Sol-Gel Technologies NASDAQ:SLGL$7.40 +0.08 (+1.09%) As of 02:34 PM EasternSol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
